XTL Biopharmaceuticals Ltd. (XTL.L) Initiates Patient Dosing In Phase 1 Clinical

[Guest guest]

XTL Biopharmaceuticals Ltd. (XTL.L) Initiates Patient Dosing In Phase

1 Clinical Trial Of XTL-2125, An Oral, Non-Nucleoside Polymerase

Inhibitor For The Treatment Of Hepatitis C

NEW YORK, May 4 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.

( " XTLbio " ) today announced the initiation of patient dosing in a

Phase 1 clinical trial of XTL-2125 for the treatment of chronic

hepatitis C. The Phase 1 trial is a placebo controlled, randomized,

dose escalating study, which will evaluate the safety, tolerability

and antiviral activity of single and multiple doses of XTL-2125. The

study will enroll 48 patients into 6 cohorts comprised of 8 patients

each (of which 2 are placebo patients). Each patient will receive a

single dose, followed by a 14-day multi-dosing regimen commencing one

week after the single dose administration.

XTL-2125 is an oral non-nucleoside hepatitis C virus polymerase

inhibitor. In pre-clinical studies, XTL-2125 has demonstrated robust

activity against the hepatitis C virus in both cell-based and in-vivo

systems. In addition, XTL-2125 has demonstrated a good safety profile

in multiple animal species.

Ron Bentsur, XTLbio's Chief Executive Officer, commented: " With the

commencement of dosing in the XTL-2125 Phase 1 trial, XTLbio is in

the unique position of having 2 novel compounds - XTL-2125 and XTL-

6865 - in clinical trials in patients with chronic hepatitis C. We

look forward to generating antiviral activity data from both studies

over the next 12 months. " Mr. Bentsur added, " The initiation of

patient dosing in the XTL-2125 study on schedule demonstrates our

strong commitment to meeting the timelines that we have set out for

our programs. "